Literature DB >> 20229648

Antigenic and genetic characteristics of influenza A(H5N1) and influenza A(H9N2) viruses and candidate vaccine viruses developed for potential use in human vaccines - February 2010.

.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20229648

Source DB:  PubMed          Journal:  Wkly Epidemiol Rec        ISSN: 0049-8114


× No keyword cloud information.
  14 in total

1.  Multi-clade H5N1 virus-like particles: Immunogenicity and protection against H5N1 virus and effects of beta-propiolactone.

Authors:  Peter Pushko; Irina Tretyakova; Rachmat Hidajat; Xiangjie Sun; Jessica A Belser; Terrence M Tumpey
Journal:  Vaccine       Date:  2018-06-07       Impact factor: 3.641

2.  Antigenic drift in H5N1 avian influenza virus in poultry is driven by mutations in major antigenic sites of the hemagglutinin molecule analogous to those for human influenza virus.

Authors:  Giovanni Cattoli; Adelaide Milani; Nigel Temperton; Bianca Zecchin; Alessandra Buratin; Eleonora Molesti; Mona Meherez Aly; Abdel Arafa; Ilaria Capua
Journal:  J Virol       Date:  2011-07-06       Impact factor: 5.103

3.  Cloned cDNA of A/swine/Iowa/15/1930 internal genes as a candidate backbone for reverse genetics vaccine against influenza A viruses.

Authors:  Porntippa Lekcharoensuk; Witthawat Wiriyarat; Nantawan Petcharat; Chalermpol Lekcharoensuk; Prasert Auewarakul; Juergen A Richt
Journal:  Vaccine       Date:  2012-01-09       Impact factor: 3.641

4.  A triclade DNA vaccine designed on the basis of a comprehensive serologic study elicits neutralizing antibody responses against all clades and subclades of highly pathogenic avian influenza H5N1 viruses.

Authors:  Fan Zhou; Guiqin Wang; Philippe Buchy; Zhipeng Cai; Honglin Chen; Zhiwei Chen; Genhong Cheng; Xiu-Feng Wan; Vincent Deubel; Paul Zhou
Journal:  J Virol       Date:  2012-04-11       Impact factor: 5.103

5.  An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus.

Authors:  Guangyu Zhao; Shihui Sun; Lanying Du; Wenjun Xiao; Zhitao Ru; Zhihua Kou; Yan Guo; Hong Yu; Shibo Jiang; Yuchun Lone; Bo-Jian Zheng; Yusen Zhou
Journal:  Virol J       Date:  2010-07-12       Impact factor: 4.099

6.  Emulsified nanoparticles containing inactivated influenza virus and CpG oligodeoxynucleotides critically influences the host immune responses in mice.

Authors:  Ming-Hsi Huang; Su-Chen Lin; Chia-Hsin Hsiao; Hsin-Ju Chao; Hung-Ren Yang; Chien-Chun Liao; Po-Wei Chuang; Huang-Pi Wu; Chiung-Yi Huang; Chih-Hsiang Leng; Shih-Jen Liu; Hsin-Wei Chen; Ai-Hsiang Chou; Alan Yung-Chih Hu; Pele Chong
Journal:  PLoS One       Date:  2010-08-19       Impact factor: 3.240

7.  Preparation of quadri-subtype influenza virus-like particles using bovine immunodeficiency virus gag protein.

Authors:  Irina Tretyakova; Rachmat Hidajat; Garrett Hamilton; Noah Horn; Brian Nickols; Raphael O Prather; Terrence M Tumpey; Peter Pushko
Journal:  Virology       Date:  2015-11-02       Impact factor: 3.616

8.  Replication and immunogenicity of swine, equine, and avian h3 subtype influenza viruses in mice and ferrets.

Authors:  Mariana Baz; Myeisha Paskel; Yumiko Matsuoka; James Zengel; Xing Cheng; Hong Jin; Kanta Subbarao
Journal:  J Virol       Date:  2013-04-10       Impact factor: 5.103

9.  Characterization of reverse genetics-derived cold-adapted master donor virus A/Leningrad/134/17/57 (H2N2) and reassortants with H5N1 surface genes in a mouse model.

Authors:  Irina Isakova-Sivak; Li-Mei Chen; Melissa Bourgeois; Yumiko Matsuoka; J Theo M Voeten; Jacco G M Heldens; Han van den Bosch; Alexander Klimov; Larisa Rudenko; Nancy J Cox; Ruben O Donis
Journal:  Clin Vaccine Immunol       Date:  2014-03-19

10.  Pathogenicity of highly pathogenic avian H5N1 influenza A viruses isolated from humans between 2003 and 2008 in northern Vietnam.

Authors:  Quynh Mai Le; Mutsumi Ito; Yukiko Muramoto; Phuong Vu Mai Hoang; Cuong Duc Vuong; Yuko Sakai-Tagawa; Maki Kiso; Makoto Ozawa; Ryo Takano; Yoshihiro Kawaoka
Journal:  J Gen Virol       Date:  2010-06-30       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.